Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | SQLE | Q14534 | 5/20 | 0.40 |
| ▸ | ICMT | O60725 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5137182 | 0.87 | — | — | |
| SCHEMBL5137183 | 0.87 | — | — | |
| SCHEMBL17728711 | 0.87 | — | — | |
| SCHEMBL19501275 | 0.86 | ALDH1A1 (0.53) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL8998758 | 0.86 | KMT2A (0.52) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL8998672 | 0.86 | KMT2A (0.52) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL8998681 | 0.86 | KMT2A (0.52) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL8998752 | 0.86 | KMT2A (0.52) | KMT2AMEN1CYP3A4ALOX15MAPT | |
| SCHEMBL18061197 | 0.84 | — | — | |
| SCHEMBL4971321 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-9737504-B2 | Dihydroorotic and acid dehydrogenase inhibitor | INSTITUTE OF MITOCHONDRIA SCIENCE, INC. (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | NAI INC. | 2016-10-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-9440913-B2 | Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient | NAI INC. (JP) | 2016-09-13 | — | — | US | disclosed |
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI INC. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI INC. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2857010-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | NAI Inc. (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2013-11-07 | — | — | US | disclosed |
| EP-2636663-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | aRigen Pharmaceuticals, Inc. (JP) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012060387-A1 | NOVEL DIHYDROXYBENZENE DERIVATIVES AND ANTIPROTOZOAL AGENT COMPRISING SAME AS ACTIVE INGREDIENT | アリジェン製薬株式会社 (JP) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166498-A1 | DIHYDROOROTIC ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | KMT2A 2734/4885MEN1 3649/4885CYP3A4 1657/4885 |
| US-20130296422-A1 | Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient | CBR3, CBR1, DHX35 | KMT2A 3955/4885MEN1 4164/4885CYP3A4 219/4885 |
| US-20160296494-A1 | DIHYDROOROTIC AND ACID DEHYDROGENASE INHIBITOR | DHODH, DPYD, DLD | KMT2A 2598/4885MEN1 3767/4885CYP3A4 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.